Palisade Bio Inc. Stock
Palisade Bio Inc. Stock
Based on 2 Buy predictions and 1 Sell predictions the sentiment towards Palisade Bio Inc. is rather balanced.
With a target price of 14 € there is potential for a 4003.17% increase which would mean more than doubling the current price of 0.34 € for Palisade Bio Inc..
Our community identified positive and negative aspects for Palisade Bio Inc. stock for the coming years. 1 users see the criterium "Company culture" as a plus for the Palisade Bio Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Palisade Bio Inc. in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Palisade Bio Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Palisade Bio Inc. | - | - | - | - | - | - | - |
| Pacira Pharmaceuticals | 1.980% | 1.000% | 12.849% | 13.483% | 9.189% | -53.670% | -58.264% |
| Rockwell Medical Inc. | -7.730% | 3.154% | -3.416% | -58.916% | -58.631% | -9.838% | -92.418% |
| Twist Bioscience Corp | -1.370% | 7.737% | 5.966% | -44.491% | -39.405% | 11.129% | -76.316% |
Comments
Palisade Bio (NASDAQ:PALI) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Show more
Ratings data for PALI provided by MarketBeat
Palisade Bio (NASDAQ:PALI) was upgraded by analysts at Wall Street Zen to a "sell" rating.
Show more
Ratings data for PALI provided by MarketBeat
Palisade Bio, Inc. (NASDAQ: PALI) had its "buy" rating re-affirmed by analysts at Brookline Capital Management. They now have a $16.00 price target on the stock.
Show more
Ratings data for PALI provided by MarketBeat